Key TakeawaysDupixent significantly reduces chronic obstructive pulmonary disease exacerbations by up to 34%.
The drug improves lung function rapidly and sustains these improvements...
Sanofi Showcases Pioneering Advances in Dermatology at EADV 2024
Key TakeawaysDupixent demonstrates rapid and durable efficacy in young children with moderate-to-severe atopic dermatitis.
Amlitelimab shows potential for quarterly dosing while maintaining a...
Key TakeawaysDupixent® recommended for approval in the EU for children aged 1-11 with EoE, based on a Phase 3 trial.
If approved, it...
Nasal Polyps Treatment Expanded: FDA Approves Dupixent for Adolescents with CRSwNP
Key TakeawaysDupixent is now the first biologic approved for adolescents with chronic rhinosinusitis with nasal polyps (CRSwNP).
The FDA approval was supported by...
Key Takeaways:Lymphoma patients in the EU with relapsed or refractory follicular and diffuse large B-cell lymphoma now have a new treatment option with...
Respiratory disease treatment is witnessing groundbreaking advancements, as shown by the latest data from Dupixent® (dupilumab) and investigational therapy itepekimab presented at the European...
Biologics development took a notable turn today as Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has issued...
The European Confederation of Pharmaceuticals Entrepreneurs (EUCOPE) has announced the addition of seven new members to its network. This significant development was revealed at...
Regeneron Pharmaceuticals and Sanofi announced that the European Commission (EC) has approved Dupixent® (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic...
Geographic Atrophy Treatments Face Setbacks as EU Drug Regulator Rejects Apellis’ Syfovre Again
For the second time in six months, the European Medicines Agency's (EMA) European Committee for Medicinal Products for Human Use (CHMP) has rejected Apellis’...
